These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 23331218)

  • 1. The practice of pre-marketing safety assessment in drug development.
    Chuang-Stein C; Xia HA
    J Biopharm Stat; 2013; 23(1):3-25. PubMed ID: 23331218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development: a report of the safety planning, evaluation, and reporting team.
    Crowe BJ; Xia HA; Berlin JA; Watson DJ; Shi H; Lin SL; Kuebler J; Schriver RC; Santanello NC; Rochester G; Porter JB; Oster M; Mehrotra DV; Li Z; King EC; Harpur ES; Hall DB
    Clin Trials; 2009 Oct; 6(5):430-40. PubMed ID: 19846894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proof of concept: a PhRMA position paper with recommendations for best practice.
    Cartwright ME; Cohen S; Fleishaker JC; Madani S; McLeod JF; Musser B; Williams SA
    Clin Pharmacol Ther; 2010 Mar; 87(3):278-85. PubMed ID: 20130568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug development: from concept to marketing!
    Tamimi NA; Ellis P
    Nephron Clin Pract; 2009; 113(3):c125-31. PubMed ID: 19729922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A safety monitoring procedure for a clinical drug development program, with application to the assessment of a novel COX-2 inhibitor.
    Bolland K; Whitehead J; Oldham M
    J Biopharm Stat; 2008; 18(4):737-49. PubMed ID: 18607805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proposed best practice for statisticians in the reporting and publication of pharmaceutical industry-sponsored clinical trials.
    Matcham J; Julious S; Pyke S; O'Kelly M; Todd S; Seldrup J; Day S
    Pharm Stat; 2011; 10(1):70-3. PubMed ID: 20187020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current development in regulation of similar biotherapeutic products in Brazil.
    Castanheira LG; Barbano DB; Rech N
    Biologicals; 2011 Sep; 39(5):308-11. PubMed ID: 21868247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does process excellence handcuff drug development?
    Koenig J
    Drug Discov Today; 2011 May; 16(9-10):377-81. PubMed ID: 21349347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Safety assessment of new products developed by the pharmaceutical industry].
    Claude JR
    Ann Pharm Fr; 2001 Sep; 59(5):324-30. PubMed ID: 11787426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The US drug safety system: role of the pharmaceutical industry.
    Gibson BR; Suh R; Tilson H
    Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):110-4. PubMed ID: 17724741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biosimilars and non-innovator biotherapeutics in India: an overview of the current situation.
    Malhotra H
    Biologicals; 2011 Sep; 39(5):321-4. PubMed ID: 21784652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systems drug discovery: a quantitative, objective approach for safer drug development.
    Bickle M
    Expert Opin Drug Discov; 2012 Sep; 7(9):757-9. PubMed ID: 22827715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A risk-based approach to scheduling audits.
    Rönninger S; Holmes M
    PDA J Pharm Sci Technol; 2009; 63(6):575-88. PubMed ID: 20169864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug safety and efficacy impaired by quality failure.
    Ekiert RJ
    Pharmazie; 2011 Jun; 66(6):467-9. PubMed ID: 21699091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How can attrition rates be reduced in cancer drug discovery?
    Moreno L; Pearson AD
    Expert Opin Drug Discov; 2013 Apr; 8(4):363-8. PubMed ID: 23373702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Industry perspectives on ICH guidelines.
    Rockhold FW
    Stat Med; 2002 Oct; 21(19):2949-57. PubMed ID: 12325111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How to improve the clinical development paradigm and its division into phases I, II and III.
    Bamberger M; Moore N; Lechat P;
    Therapie; 2011; 66(4):331-4, 327-30. PubMed ID: 21851796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The importance of triaging in determining the quality of output from high-throughput screening.
    Jones P; McElroy S; Morrison A; Pannifer A
    Future Med Chem; 2015; 7(14):1847-52. PubMed ID: 26419190
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.